1-2 of 2
Pankaj Kumar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

Qiao-Li Wang, Chao Ma, Chen Yuan, Qian Shi, Brian M. Wolpin, Yin Zhang, Charles S. Fuchs, Jeffrey Meyer, Tyler Zemla, En Cheng, Priya Kumthekar, Katherine A. Guthrie, Felix Couture, Philip Kuebler, Pankaj Kumar, Benjamin Tan, Smitha Krishnamurthi, Richard M. Goldberg, Alan Venook, Charles Blanke, Anthony F. Shields, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Kimmie Ng
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (14): 2621–2630.
https://doi.org/10.1158/1078-0432.CCR-23-0447
Published: 14 July 2023
View article titled, Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Open the PDF for Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance) in another window
Includes: Supplementary data
Journal Articles

YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer

Fan Li, Yan Xu, Bovey Liu, Pankaj Kumar Singh, Wei Zhao, Jiankang Jin, Guangchun Han, Ailing W. Scott, Xiaochuan Dong, Longfei Huo, Lang Ma, Melissa Pool Pizzi, Ying Wang, Yuan Li, Kazuto Harada, Min Xie, Heath D. Skinner, Sheng Ding, Linghua Wang, Sunil Krishnan, Randy L. Johnson, Shumei Song, Jaffer A. Ajani
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2264–2277.
https://doi.org/10.1158/1078-0432.CCR-18-1029
Published: 01 April 2019
View article titled, YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer
Open the PDF for YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer in another window
Includes: Supplementary data